Susquehanna International Group, LLP Altimmune, Inc. Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

22 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$5.5 - $8.1 $833,250 - $1.23 Million	-151,500 Reduced 30.61%	343,500 $2.11 Million
Q2 2024 Aug 15, 2024	SELL	$5.91 - $10.23 $573,861 - $993,333	-97,100 Reduced 16.4%	495,000 $3.29 Million
Q1 2024 May 07, 2024	SELL	$8.22 - $13.81 $2.52 Million - $4.24 Million	-306,800 Reduced 34.13%	592,100 $6.03 Million
Q4 2023 Feb 14, 2024	BUY	$2.14 - $11.62 $1.34 Million - $7.25 Million	624,200 Added 227.23%	898,900 $10.1 Million
Q3 2023 Nov 14, 2023	BUY	$2.4 - $3.45 $423,360 - $608,580	176,400 Added 179.45%	274,700 $714,000
Q2 2023 Aug 11, 2023	SELL	$3.45 - $5.97 $341,550 - $591,030	-99,000 Reduced 50.18%	98,300 $346,000
Q1 2023 May 16, 2023	SELL	$4.19 - $16.83 $968,728 - $3.89 Million	-231,200 Reduced 53.96%	197,300 $832,000
Q4 2022 Feb 14, 2023	BUY	$8.74 - $16.45 $474,582 - $893,235	54,300 Added 14.51%	428,500 $7.05 Million
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $196,328 - $412,344	18,400 Added 5.17%	374,200 $4.78 Million
Q2 2022 Aug 15, 2022	BUY	$3.94 - $11.77 $467,678 - $1.4 Million	118,700 Added 50.06%	355,800 $4.16 Million
Q1 2022 May 16, 2022	SELL	$5.9 - $9.45 $74,340 - $119,069	-12,600 Reduced 5.05%	237,100 $1.44 Million
Q4 2021 Feb 14, 2022	BUY	$8.69 - $12.48 $83,424 - $119,808	9,600 Added 4.0%	249,700 $2.29 Million
Q3 2021 Nov 15, 2021	SELL	$8.43 - $16.81 $626,349 - $1.25 Million	-74,300 Reduced 23.63%	240,100 $2.72 Million
Q2 2021 Aug 11, 2021	BUY	$9.85 - $16.46 $465,905 - $778,558	47,300 Added 17.71%	314,400 $3.1 Million
Q1 2021 May 17, 2021	BUY	$12.71 - $24.31 $2.51 Million - $4.8 Million	197,400 Added 283.21%	267,100 $3.77 Million
Q4 2020 Feb 16, 2021	SELL	$7.84 - $14.22 $815,360 - $1.48 Million	-104,000 Reduced 59.87%	69,700 $786,000
Q3 2020 Nov 16, 2020	SELL	$9.93 - $33.26 $2.37 Million - $7.93 Million	-238,300 Reduced 57.84%	173,700 $2.29 Million
Q2 2020 Aug 14, 2020	BUY	$2.9 - $10.71 $928,000 - $3.43 Million	320,000 Added 347.83%	412,000 $4.41 Million
Q1 2020 May 15, 2020	BUY	$1.69 - $3.8 $133,848 - $300,960	79,200 Added 618.75%	92,000 $295,000
Q2 2019 Aug 14, 2019	SELL	$2.19 - $3.4 $75,117 - $116,620	-34,300 Reduced 72.82%	12,800 $30,000
Q1 2019 May 15, 2019	BUY	$2.54 - $4.54 $79,756 - $142,556	31,400 Added 200.0%	47,100 $137,000
Q4 2018 Feb 14, 2019	BUY	$1.72 - $7.24 $27,004 - $113,668	15,700 New	15,700 $32,000

Others Institutions Holding ALT

# of Institutions

185

Shares Held

39.2M

Call Options Held

913K

Put Options Held

743K

Black Rock Inc. New York, NY

5.32M
Shares

$40.5 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

4.98M
Shares

$37.9 Million
0.0% of portfolio
Ameriprise Financial Inc Minneapolis, MN

3.88M
Shares

$29.5 Million
0.01% of portfolio
State Street Corp Boston, MA

3.41M
Shares

$26 Million
0.0% of portfolio
Tang Capital Management LLC San Diego, CA

2.75M
Shares

$20.9 Million
1.44% of portfolio

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $373M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account